Cocrystal Pharma, Inc. (NASDAQ:COCP) Sees Significant Drop in Short Interest

Cocrystal Pharma, Inc. (NASDAQ:COCP) was the recipient of a large drop in short interest during the month of October. As of October 31st, there was short interest totalling 2,000 shares, a drop of 94.5% from the October 15th total of 36,200 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily volume of 17,600 shares, the days-to-cover ratio is presently 0.1 days.

Analysts Set New Price Targets

Separately, HC Wainwright decreased their price objective on Cocrystal Pharma from $10.00 to $7.00 and set a “buy” rating for the company in a research report on Thursday, August 22nd.

Cocrystal Pharma Stock Performance

NASDAQ:COCP traded up $0.01 on Tuesday, reaching $1.76. The company’s stock had a trading volume of 11,652 shares, compared to its average volume of 20,845. The firm has a market cap of $17.90 million, a PE ratio of -0.99 and a beta of 1.45. Cocrystal Pharma has a 1-year low of $1.33 and a 1-year high of $3.10. The business’s 50-day moving average price is $1.80 and its two-hundred day moving average price is $1.99.

Cocrystal Pharma (NASDAQ:COCP) last released its earnings results on Wednesday, August 14th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.02). As a group, sell-side analysts expect that Cocrystal Pharma will post -1.94 EPS for the current year.

About Cocrystal Pharma

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.